How to Evaluate Staff Competency and Site Infrastructure in Clinical Trial Feasibility

Introduction: Why Competency and Infrastructure Matter

Assessing the competency of site staff and the adequacy of site infrastructure is a cornerstone of clinical trial feasibility planning. Regulatory bodies, including the FDA, EMA, and MHRA, expect sponsors and CROs to verify that trial sites are equipped—both in terms of people and facilities—to conduct a study in compliance with protocol and Good Clinical Practice (GCP).

Failures in infrastructure (e.g., lack of -80°C freezers or ECG machines) or human resources (e.g., inexperienced or overcommitted investigators) have been linked to protocol deviations, regulatory findings, delayed enrollment, and data integrity issues. Therefore, staff competency and site infrastructure must be rigorously evaluated before selecting a site for activation.

This article provides a detailed checklist, real-world examples, and documentation standards for evaluating clinical trial site staffing and infrastructure readiness as part of the feasibility process.

Staff Competency Domains to Evaluate

To ensure high-quality clinical trial conduct, sponsors must evaluate staff across three dimensions: qualifications, availability, and experience. This includes both the Principal Investigator (PI) and sub-investigators, as well as study coordinators, pharmacists, laboratory staff, and regulatory personnel.

Key Evaluation Areas:

• Professional background and therapeutic area expertise of the PI
• GCP training and protocol-specific training for all staff
• Staff-to-patient ratio and workload capacity
• Experience with similar trials (e.g., Phase II oncology studies)
• Involvement of pharmacy, radiology, and laboratory teams (as applicable)
• Ability to manage eCRF systems, IRT, and digital reporting platforms

Sample Staffing Competency Table:

Sites with high PI workload or staff with outdated training should be flagged during feasibility review. Investigators should not be simultaneously managing more than 3–4 active trials unless strong support infrastructure exists.

Infrastructure Evaluation: What to Check

Site infrastructure refers to the physical, technical, and logistical systems required to execute a clinical trial. This varies by protocol but typically includes:

• Exam rooms and consenting areas
• IP storage with restricted access and temperature control
• Freezers (-20°C and -80°C) with temperature monitoring and backup
• Sample processing areas (centrifuge, laminar flow hood)
• On-site or contract laboratories
• Emergency equipment (crash cart, AED) where medically required
• Document archiving and IT infrastructure (secure, validated)

Infrastructure should also support accessibility for patients (transportation, parking, ramps) and comply with biosafety and infection control standards, especially for infectious disease trials.

Example Infrastructure Readiness Table:

Essential Documents for Validation

Documentation is critical to confirm the above claims. Sponsors and feasibility teams should request:

• PI and staff CVs (signed and dated)
• GCP training certificates (valid within 2 years)
• Organizational chart for clinical research team
• Calibration logs (centrifuges, freezers, ECG machines)
• Preventive maintenance reports for key equipment
• Facility layout with marked clinical trial areas

This documentation should be reviewed during pre-study visits (PSVs) and retained in the sponsor’s Trial Master File (TMF).

Red Flags in Staff and Infrastructure Evaluation

Feasibility reviewers should be alert to signs that may indicate poor site performance or inspection risk:

• No full-time study coordinator assigned
• High staff turnover or absence of cross-trained backups
• No documentation of equipment validation/calibration
• Shared or non-dedicated clinical space
• Delayed response in providing requested documents
• Unavailability of PI for protocol discussions or SIV

Regulatory Expectations for Staff and Site Evaluation

ICH E6(R2) guidelines require sponsors to confirm that trial sites are adequately staffed and equipped. Specifically:

• Section 4.1: PI must supervise the trial personally and ensure team compliance
• Section 5.6: Sponsors must ensure investigators are qualified by training and experience
• Section 5.18: Site monitoring must verify that facilities remain suitable throughout the trial

The FDA and EMA also expect feasibility documentation to support site selection decisions. This includes CVs, inspection histories, SOPs, and any feasibility scoring tools used.

Scoring Model for Site Selection Based on Staff and Infrastructure

Sites scoring below 60% may require CAPA, follow-up, or exclusion from site selection.

Best Practices for Sponsors and CROs

• Conduct feasibility interviews with both PI and study coordinator
• Use site pre-qualification forms and remote assessments
• Maintain standardized staff/infrastructure checklists within feasibility SOPs
• Document all reviews in the TMF and CTMS
• Confirm readiness prior to SIV using updated documents

Conclusion

Competent staff and adequate infrastructure form the foundation of any successful clinical trial. Feasibility teams must adopt a structured, evidence-based approach when evaluating these critical site attributes. Through a combination of interviews, document review, and physical audits, sponsors can ensure that selected sites are capable of meeting protocol demands, regulatory expectations, and patient safety obligations. By integrating staff and infrastructure assessments into formal feasibility workflows, organizations reduce risk, improve enrollment, and enhance data quality across their clinical research programs.